Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer

February 17th 2017

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

In MPC, Gemcitabine/Nab-Paclitaxel More Cost Effective Than With FOLFIRINOX

February 16th 2017

Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Induction Regimen Achieves 80% DCR in Advanced Pancreatic Cancer

February 14th 2017

The combination of nanoparticle albumin-bound-paclitaxel and gemcitabine led to no new or unexpected adverse events in a small study of patients with locally advanced pancreatic cancer.

Analysis Confirms Survival Benefit With Nanoliposomal Irinotecan Regimen in Pancreatic Cancer

February 7th 2017

Patients with metastatic pancreatic ductal adenocarcinoma lived longer and had slowing of disease progression when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Little Correlation Between Phase II, III Trials in Advanced Pancreatic Cancer

February 7th 2017

Few phase II trials in advanced pancreatic cancer conformed to recommended design characteristics for pilot trials, a contributing factor to lack of success in the disease, Australian investigators reported.

Napabucasin Linked With Objective Responses in Advanced CRC

February 7th 2017

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.

PD-1 Inhibitor Active in Advanced Liver Cancer

February 1st 2017

Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.

Dr. Talamonti on Surgical Advancements in Pancreatic Cancer

January 25th 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the recent surgical advancements in pancreatic cancer.

Dr. Mariette on a Study of Postoperative Mortality After Esophageal and Gastric Cancer Surgery

January 25th 2017

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Vemurafenib Adds to PFS in BRAF-mutant mCRC

January 25th 2017

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

January 24th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC

January 24th 2017

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Dr. Terashima on Bursectomy for Subserosal and Serosal Gastric Cancer

January 24th 2017

Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

Trend Toward Better PFS With Four-Drug CRC Regimen

January 24th 2017

Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.

Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

January 24th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.

Dr. Muro on Results of PaFF-K Study in Colorectal Cancer

January 23rd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the results of the PaFF-K study in metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Differences in Mutation Rates Between Right- and Left-Sided CRC

January 22nd 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, the University of Pennsylvania, discusses a study investigating differences in mutation rates between right- and left-sided colorectal cancer.

Cabozantinib Active in Neuroendocrine Tumors

January 22nd 2017

In a single-arm phase II study, cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors.

Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

January 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.